SCRI

Sarah Cannon Research Institute to Present Latest Cancer Research Insights at 2024 ASCO® Annual Meeting

Retrieved on: 
木曜日, 5月 30, 2024
Research, Genetics, Clinical Trials, Biotechnology, General Health, Pharmaceutical, Health, Science, Oncology, Other Science, Relapse, Follicular lymphoma, Paclitaxel, Finish line, Drug development, Metastatic breast cancer, Breast cancer, Tumor microenvironment, Sarah Cannon Research Institute, Breast, Lead, Master, Consolidation, HealthOne, Durvalumab, Meta-analysis, CDT, OU Health, Total cost, PD-L1, Survival, Clinical trial, Quality, MPH, Endometrial cancer, NSCLC, SCRI, ASCO, Safety, BCMA, Society, Cetuximab, Doctor of Philosophy, Efficacy, Spacecraft, Metastasis, Monoclonal antibody, Acute myeloid leukemia, Abstract, HCA Healthcare, Role, Annual general meeting, Birth control

“We look forward to connecting with colleagues from around the world at ASCO’s Annual Meeting to discuss the latest developments in advancing therapies for cancer patients,” says Howard A.

Key Points: 
  • “We look forward to connecting with colleagues from around the world at ASCO’s Annual Meeting to discuss the latest developments in advancing therapies for cancer patients,” says Howard A.
  • To learn more about our research experts, visit our Leadership Page .
  • “Clinical Trial Participation and End-of-Life Care Among Older Adults: A Multi-Center Longitudinal Observational Cohort Analysis of 121,717 Patients with Cancer,” Dr.
  • “Performance of Comprehensive Genomic Profiling versus Single Gene Testing in Guideline-Recommended Biomarker Selection in Non-Small Cell Lung Cancer,” Dr. V. Subbiah, 1:30 p.m. - 4:30 p.m. CDT, Hall A.

Sarah Cannon Research Institute Expands into East Tennessee Through Collaboration with Tennessee Cancer Specialists

Retrieved on: 
木曜日, 5月 23, 2024
Oncology, Health, Clinical Trials, Research, Pharmaceutical, Science, MD, Sarah Cannon Research Institute, Patient, Cancer, Physician, SCRI, FDA, Travel, Pharmaceutical industry

Sarah Cannon Research Institute (SCRI), one of the world’s leading oncology research organizations conducting community-based clinical trials, announced today a collaboration with Tennessee Cancer Specialists , an independent, private practice oncology group, based in Knoxville, Tenn.

Key Points: 
  • Sarah Cannon Research Institute (SCRI), one of the world’s leading oncology research organizations conducting community-based clinical trials, announced today a collaboration with Tennessee Cancer Specialists , an independent, private practice oncology group, based in Knoxville, Tenn.
  • The collaboration will provide expanded research options to people facing cancer throughout the East Tennessee region.
  • “Our talented physicians have long understood the importance of clinical trials and the cutting-edge options they can provide to patients,” said President Tracy W. Dobbs, MD, oncologist with Tennessee Cancer Specialists.
  • Tennessee Cancer Specialists will offer clinical trials with SCRI beginning in summer 2024.

SCRI Announces a Collaboration with AstraZeneca Focused on Technology Enhancements & Innovative Operational Model to Advance Cancer Research

Retrieved on: 
水曜日, 2月 28, 2024
Research, Technology, Clinical Trials, Software, Biotechnology, Pharmaceutical, Health, Data Management, Science, Oncology, AstraZeneca, Electronic data capture, Physician, SCRI, Drug development, Data collection, EHR, Sarah Cannon Research Institute, Electronic health record, Patient, Clinical trial, E2E, EDC, Cancer, Pharmaceutical industry

Sarah Cannon Research Institute (SCRI), one of the world’s leading oncology research organizations conducting community-based clinical trials, announced today a collaboration with AstraZeneca, a global, science-led biopharmaceutical company, aimed at advancing innovative technology and operational synergies to enhance the delivery of oncology clinical trials.

Key Points: 
  • Sarah Cannon Research Institute (SCRI), one of the world’s leading oncology research organizations conducting community-based clinical trials, announced today a collaboration with AstraZeneca, a global, science-led biopharmaceutical company, aimed at advancing innovative technology and operational synergies to enhance the delivery of oncology clinical trials.
  • Working together, SCRI and AstraZeneca will implement modern solutions to accelerate clinical trial delivery timelines, reduce site burden, and enhance U.S. enrollment.
  • To date, this advancement is decreasing site-based data entry time, reducing manual labor, lowering monitoring costs, improving data quality, and accelerating clinical trial decision-making overall.
  • “Working with SCRI to enhance U.S. enrollment and streamline clinical trial data collection is a tremendous opportunity to increase the diversity of clinical trial participants in the U.S. and accelerate clinical trial delivery timelines.

Pepperdine Graziadio Business School to host 9th annual Healthcare Symposium: 'Elevating Healthcare: Exploring Solutions for the Future'

Retrieved on: 
月曜日, 2月 12, 2024
Pepperdine University, Entrepreneurship, Health, SCRI, Future, MBA, Sarah Cannon Research Institute, Faculty, Health care, University, COVID-19, Specialization, Pepperdine Graziadio Business School, COVID, Policy, PST, Knowledge, Heart, Doorway, Student, Management

MALIBU, Calif., Feb. 12, 2024 /PRNewswire/ -- The Pepperdine Graziadio Business School will host " Elevating Healthcare: Exploring Solutions for the Future ," its 9th annual Healthcare Symposium on Thursday, Feb. 29.

Key Points: 
  • MALIBU, Calif., Feb. 12, 2024 /PRNewswire/ -- The Pepperdine Graziadio Business School will host " Elevating Healthcare: Exploring Solutions for the Future ," its 9th annual Healthcare Symposium on Thursday, Feb. 29.
  • The symposium is a marquee Graziadio event that brings industry leaders, experts and professionals together to delve into critical issues shaping the future of healthcare.
  • Pepperdine Graziadio Business School offers an array of courses tailored to meet the evolving demands of the healthcare industry.
  • The Pepperdine Graziadio Business School — for more than 50 years — has challenged individuals to think boldly and drive meaningful change within their industries and communities.

PKF O'Connor Davies Releases 2024 Long Island Economic Survey Results

Retrieved on: 
金曜日, 1月 26, 2024
Intelligence, SCRI, PKF, Siena College Research Institute

NEW YORK, Jan. 26, 2024 /PRNewswire-PRWeb/ -- PKF O'Connor Davies, one of the nation's largest accounting, tax and advisory practices, today announced the results of its Long Island Economic Survey – Outlook 2024. The annual survey invites local leaders to share their perspectives on the current state of doing business in New York, as well as their outlook on the regional economy for the coming year. In addition, the report illuminates a number of critical issues affecting the ability of businesses and their leaders to compete successfully in today's economy.

Key Points: 
  • NEW YORK, Jan. 26, 2024 /PRNewswire-PRWeb/ -- PKF O'Connor Davies, one of the nation's largest accounting, tax and advisory practices, today announced the results of its Long Island Economic Survey – Outlook 2024.
  • "Our Long Island Economic Survey has become an invaluable resource for our clients and the greater Long Island business community to better understand and adapt to the changing economic, political and social circumstances impacting the region," said Jeffery S. Davoli, Co-Partner-in-Charge of PKF O'Connor Davies' Hauppauge Office.
  • Since 1995, PKF O'Connor Davies' Long Island Economic Survey has detailed trends affecting the regional business climate, local leaders' plans to enhance their businesses and strategies to address challenging economic headwinds.
  • To download the Long Island Economic Survey – Outlook 2024, visit https://www.pkfod.com/outlook-2024-long-island-economic-survey-results/ .

The US Oncology Network Further Expands Its Nashville, Tennessee Footprint and Research Expertise with the Addition of SCRI Oncology Partners

Retrieved on: 
火曜日, 12月 19, 2023
Research, Clinical Trials, Practice Management, Biotechnology, Managed Care, General Health, Health, Science, Oncology, Other Science, Network, Physician, FDA, Sarah Cannon Research Institute, Clinical trial, The Network, SCRI, Growth, MPH, Patient, Nursing

The US Oncology Network ( The Network ), the largest organization of its kind dedicated to advancing local cancer care and better patient outcomes, announced today that SCRI Oncology Partners has joined The Network.

Key Points: 
  • The US Oncology Network ( The Network ), the largest organization of its kind dedicated to advancing local cancer care and better patient outcomes, announced today that SCRI Oncology Partners has joined The Network.
  • SCRI Oncology Partners, located in Nashville, Tenn., is a dedicated cancer treatment center led by globally recognized oncologists with disease expertise in cancer care and clinical research.
  • “Increasing access to clinical trials and enhancing local cancer care are significant priorities for us,” said Jason Hammonds, president, The US Oncology Network.
  • In 2022, SCRI formed a joint venture with former US Oncology Research, the research arm of The US Oncology Network, to expand clinical trial access across the country.

LIXTE Biotechnology Provides Update on Clinical Progress and Expanding Collaborations

Retrieved on: 
月曜日, 11月 13, 2023
Doxorubicin, Squamous-cell carcinoma, Research, Netherlands Cancer Institute, City, Progression-free survival, Sarcoma, BioRxiv, Clinical trial, Patient, Northwestern, MD Anderson Cancer Center, GEIS, Monroe Dunaway Anderson, GSK, PP2A, ASTS, Sarah Cannon Research Institute, SCRI, Cancer, University, Partnership, NKI, Immunotherapy, Pharmaceutical industry

(“LIXTE” or the “Company”) (Nasdaq: LIXT and LIXTW), a clinical-stage pharmaceutical company developing a new class of cancer therapy to enhance chemotherapy and immunotherapy benefit, today provided an update on its progress.

Key Points: 
  • (“LIXTE” or the “Company”) (Nasdaq: LIXT and LIXTW), a clinical-stage pharmaceutical company developing a new class of cancer therapy to enhance chemotherapy and immunotherapy benefit, today provided an update on its progress.
  • GSK will provide dostarlimab and financial support for the clinical trial.
  • In addition to MD Anderson, the trial also will be open at Northwestern University’s Robert H. Lurie Comprehensive Cancer Center.
  • This trial will enroll up to 170 patients and will begin in partnership with GEIS clinical sites.

Sarah Cannon Research Institute to Present Latest Research Insights at the 2023 ASH Annual Meeting & Exposition

Retrieved on: 
木曜日, 12月 7, 2023
Health, Science, Research, Clinical Trials, Oncology, HCA Healthcare, Methodist Hospital, Annual general meeting, PST, St. Elizabeth Healthcare (Kentucky), Sickle cell disease, Bone marrow, ASH, BMT, BSN, Malignancy, Exposition, Sarah Cannon Research Institute, SCRI, Abstract, Nursing care plan, Nivolumab, Society, Physician, Monomethyl auristatin E, Safety, McKesson Corporation, Pharmaceutical industry, Nursing, Vaccine, Dacarbazine, MD, Doxorubicin, Texas Oncology, Patient

Sarah Cannon Research Institute ( SCRI ) announced today that more than 80 abstracts and presentations have been selected for inclusion at the 65th American Society of Hematology (ASH) Annual Meeting & Exposition .

Key Points: 
  • Sarah Cannon Research Institute ( SCRI ) announced today that more than 80 abstracts and presentations have been selected for inclusion at the 65th American Society of Hematology (ASH) Annual Meeting & Exposition .
  • Hosted in San Diego and online from Dec. 9-12, the meeting is the year’s most comprehensive global hematology event.
  • At this year’s ASH Annual Meeting & Exposition, SCRI investigators, including physicians from The US Oncology Network , will discuss groundbreaking research in malignant and non-malignant blood cancer, CAR T-Cell therapy, real-world outcomes, and targeted immunotherapies.
  • Investigators highlighting research at this year’s ASH Annual Meeting & Exposition represent studies being conducted across SCRI, Sarah Cannon Transplant & Cellular Therapy Network, and partners from The US Oncology Network and Ontada.

The Surgery Center of Rhode Island is Designated a "Top Ambulatory Surgery Center" by The Leapfrog Group for Clinical Quality and Patient Safety

Retrieved on: 
水曜日, 12月 13, 2023
Patient safety organization, Safety, Ambulatory Surgery Center Association, Surgeon, Nose, CSA, Patient, Insurance, ASC, SCRI, Partnership, Medicare, Ear, Physician, Ophthalmology, Nursing

The Leapfrog Group is a national watchdog organization that is widely acknowledged as the toughest standard-setter for healthcare safety and quality.

Key Points: 
  • The Leapfrog Group is a national watchdog organization that is widely acknowledged as the toughest standard-setter for healthcare safety and quality.
  • "This award reflects the commitment to the highest of standards set by the physicians and staff at SCRI.
  • Receiving this award shows that staff members at The Surgery Center of Rhode Island are highly committed to meeting those consumer demands.
  • We are honored to be among the select few receiving this prestigious award, reflecting our ongoing pledge to patient safety and community well-being."

OneOncology Appoints Ian Flinn, MD, PhD as Chief Scientific Officer

Retrieved on: 
月曜日, 11月 20, 2023
Research, Johns Hopkins, Bone marrow, Association rule learning, Patient, St Vincent's Hospital, Sydney, Hematology, Sarah Cannon Research Institute, SCRI, Sidney Kimmel, Doctor of Philosophy, Management, Pharmaceutical industry, MD

NASHVILLE, Tenn., Nov. 20, 2023 /PRNewswire/ -- OneOncology, the fastest-growing national platform for independent oncology practices, has appointed Ian Flinn, MD, PhD, as Chief Scientific Officer.

Key Points: 
  • NASHVILLE, Tenn., Nov. 20, 2023 /PRNewswire/ -- OneOncology, the fastest-growing national platform for independent oncology practices, has appointed Ian Flinn, MD, PhD, as Chief Scientific Officer.
  • OneOncology appoints Ian Flinn, MD, PhD, as Chief Scientific Officer to oversee OneR, OneOncology's research network.
  • Dr. Flinn will also service as Chief Scientific Officer at Tennessee Oncology.
  • "Dr. Flinn will be a valuable resource for our practice partners to advance their clinical trial programs," said Davey Daniel, MD, Chief Medical Officer, OneOncology.